Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | FABP7 | O15540 | 1/20 | 0.35 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325536 | 1.00 | MAPT (0.43) | MAPTGAATSHRNPSR1KDM4E | |
| SCHEMBL29599645 | 1.00 | MAPT (0.43) | MAPTGAATSHRNPSR1KDM4E | |
| SCHEMBL2218168 | 1.00 | MAPT (0.43) | MAPTGAATSHRNPSR1KDM4E | |
| SCHEMBL3570843 | 1.00 | MAPT (0.43) | MAPTGAATSHRNPSR1KDM4E | |
| SCHEMBL8120909 | 1.00 | MAPT (0.43) | MAPTGAATSHRNPSR1KDM4E | |
| SCHEMBL21243773 | 0.83 | ESR2 (0.38) | MAPTGAAKDM4ESMN1; SMN2MAPK1 | |
| SCHEMBL21243769 | 0.83 | ESR2 (0.38) | MAPTGAAKDM4ESMN1; SMN2MAPK1 | |
| SCHEMBL1202734 | 0.83 | ESR2 (0.38) | MAPTGAAKDM4ESMN1; SMN2MAPK1 | |
| SCHEMBL28787105 | 0.82 | MAPT (0.53) | MAPTGAATSHRNPSR1KDM4E | |
| SCHEMBL27398624 | 0.82 | MAPT (0.53) | MAPTGAATSHRNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263608-B2 | Melanocortin receptor-specific spiro-piperidine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010037081-A1 | MELANOCORTIN RECEPTOR-SPECIFIC SPIRO-PIPERIDINE COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| CN-101525374-A | Pentapeptide derivative, preparation method and applications thereof | INST PHARM & TOXICOLOGY AMMS (CN) | 2009-09-09 | — | — | CN | disclosed |
| EP-1603912-B1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-07-18 | — | — | EP | disclosed |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-07-05 | — | — | US | disclosed |
| US-20070037823-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-02-15 | — | — | US | disclosed |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2006-10-26 | — | — | US | disclosed |
| EP-1606278-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-21 | — | — | EP | disclosed |
| EP-1603911-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005054278-A1 | SUBSTITUTED N-BENZYL-LACTAM DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-16 | — | — | WO | disclosed |
| EP-1538159-A1 | Substituted N-benzyl-lactam derivatives as melanocortin-4 receptor agonists | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2005-06-08 | — | — | EP | disclosed |
| EP-1468999-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004083198-A1 | SUBSTITUTED CYCLOHEXYL AND PIPERIDINYL DERIVATES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004083208-A1 | SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2004-09-30 | — | — | WO | disclosed |
| EP-1460069-A1 | Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-09-22 | — | — | EP | disclosed |
| EP-1460073-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-09-22 | — | — | EP | disclosed |
| EP-1460070-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MyoContract Ltd. (CH) | 2004-09-22 | — | — | EP | disclosed |
| CN-1467219-A | Pentapeptide analogues, their preparation and their use | 中国人民解放军军事医学科学院毒物药 | 2004-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037823-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | MAPT 3852/4885GAA 3903/4885TSHR 222/4885 |
| US-20110178080-A1 | Melanocortin Receptor-Specific Spiro-Piperidine Compounds | MC1R, MC5R, MC3R | MAPT 2005/4885GAA 4186/4885TSHR 66/4885 |
| US-20070155783-A1 | Substituted cyclohexyl and piperidinyl derivates as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | MAPT 3490/4885GAA 3177/4885TSHR 212/4885 |
| US-20060241123-A1 | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators | MC4R, MC5R, MC3R | MAPT 3664/4885GAA 3805/4885TSHR 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.